This article reviews the recent changes in the development and regulation of medicine/medical device combination products. It considers the impact of recent technological advances, particularly in the areas of theranostics and tissue engineering, upon the regulations. Suggestions are made as to how companies should approach such interface products. The current debate on the future regulation of tissue-engineered products is also discussed.
JefferysDBThe regulation of medical devices and the role of the Medical Devices Agency. Br J Clin Pharmacol.2001;52:229–235.
2.
JefferysDBComparison of the regulatory controls for medical devices and medicinal products. Int J Pharm Med.2001;15:125–130.
3.
Guideline for the Clarification of Medical Devices MEDDEV 2.4/1 Rev 07–2001.
4.
Council Directive 93/42/EEC of June 1993.
5.
2001/83/EC Directive of the European Parliament and of the Council of November 6, 2001. 2001 in the Community Code Relating to Medical Products for Human Use OJEC L311.
6.
Directive 200/70 EC of 16 December 2000 OJEC L313 of 13.12.2000 as last amended by Directive 2001/104 EC.
7.
Council Directive 90/385 EEC of 20 June 1990 on the approximation of the laws of the Member States relating to active implantable medical devices 4 189. July 20, 1990.
8.
Opinion on the state of the art concerning tissue engineering. Doc. SANCO/SCMPMD/2001/0006.
9.
Council Directive 98/79 EC of the European Parliament and of the Council of the 27 October 1998 on in vitro diagnostics medical devices L331. December 7, 1998.
10.
A code of practice for tissue banks—providing tissues of human origin for therapeutic purposes.Department of Health; 2001: ISBN 1. 84182, 231,5.
